Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market 2017-2025 - Valeant (Salix Pharmaceuticals) will Emerge the Market Leader - Research and Markets

Research and Markets
Posted on: 03 Oct 17

The "Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering.

The irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 780.29 Mn by 2025, expanding at a CAGR of 13.89% from 2017 - 2025.

Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as breakthrough step in the long struggle to discover effective treatment for IBS-D.

Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due to the introduction of the said novel drugs.

Commenting on the competitive scenario, the IBS-D drugs market is fragmented with no clear leader in terms of market revenue share. However, it is expected that with gradual approvals in the international markets, Valeant (Salix Pharmaceuticals) will emerge the market leader in the overall IBS drugs market with products for both IBS-D and IBS-C treatment.

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 IBS-D Drugs Market: Market Dynamics and Outlook

Chapter 4 Global IBS-D Drugs Market Analysis, by Drugs

Chapter 5 Global IBS-D Drugs Market Analysis, By Prescription Type

Chapter 6 Global IBS-D Drugs Market Analysis, By Geography

Chapter 7 Company Profiles

  • Astellas Pharmaceuticals
  • Actavis
  • Pfizer
  • GlaxoSmithKline
  • Salix Pharmaceuticals Ltd
  • AstraZenenca

For more information about this report visit

View source version on

Business Wire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.